Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SIBN
HOLDSI-BONE, Inc. · Healthcare · United States · $737M · Avg Vol: $10M/d
COMPANY DESCRIPTION
SI-BONE is a leading medical device company pioneering minimally invasive surgical solutions for joint dysfunction in the sacroiliac (SI) joint, sacrum, and pelvis. The company's flagship iFuse Implant System is backed by an extensive body of clinical evidence, making it the gold standard for SI joint fusion procedures. Its competitive moat is secured by robust patent protection, exclusive surgeon training programs, and favorable reimbursement coverage from major insurance payors.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.4M | 138.9M | 167.2M | 200.9M | 23.6% | 206.2M | 231.6M | 266.6M | 15.2% |
| EPS | -1.79 | -1.13 | -0.75 | -0.44 | — | -0.38 | -0.43 | -0.35 | — |
| Shares | 34.7M | 40.7M | 42.1M | 43.6M | +25.7% | 44.3M | — | — | — |
| Debt | 39.4M | 39.0M | 37.5M | 36.7M | -2.4% | 42.9M | — | — | — |
| Equity | 98.3M | 169.4M | 167.0M | 177.5M | 21.8% | — | — | — | — |
| Op CF | -41.7M | -18.7M | -12.4M | -0.7M | — | 1.9M | — | — | — |
| Inv CF | -2.8M | -59.8M | 12.6M | 4.2M | — | — | — | — | — |
| Fin CF | 2.2M | 90.9M | 2.0M | 3.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SIBN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SIBN | SI-BONE, Inc.(you) | $737M | 42 | HOLD |
| CTKB | Cytek Biosciences, Inc. | $576M | 40 | HOLD |
| CERS | Cerus Corporation | $587M | 46 | HOLD |
| QDEL | QuidelOrtho Corporation | $1.1B | 47 | HOLD |
| KIDS | OrthoPediatrics Corp. | $485M | 50 | HOLD |
| NPCE | NeuroPace, Inc. | $505M | 32 | SELL |
| OFIX | Orthofix Medical Inc. | $455M | 51 | HOLD |
| BBNX | Beta Bionics, Inc. | $706M | 21 | SELL |
| CBLL | CeriBell, Inc. | $642M | 22 | SELL |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | 26 | SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%